ACE2 and Alzheimer disease: In the first cohort from the Religious Order Study (n = 60), ACE2 protein levels were evaluated according to (i) the clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), or AD; (ii) the neuropathological diagnosis of AD (ABC scoring) and the antemortem assessment of cognitive function.